Holen Sie sich die Stockscreener-App
0.00
100.00%
-2.27
Handel nachbörslich:
2.25
2.25
+
Schlusskurs vom Vortag:
$2.27
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$227.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-299.80M
KGV:
0.00
EPS:
-2.84
Netto-Cashflow:
$-217.49M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$7.25
Acelyrin Inc Stock (SLRN) Company Profile
Firmenname
Acelyrin Inc
Sektor
Branche
Telefon
805-456-4393
Adresse
4149 LIBERTY CANYON RD., AGOURA HILLS
Vergleichen Sie SLRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
0.00 | 227.15M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-09-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-30 | Eingeleitet | Jefferies | Buy |
| 2023-05-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-05-30 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-30 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Acelyrin Inc Aktie (SLRN) Neueste Nachrichten
Acelyrin Requests to Dismiss Class Action Filed by Investors - TradingView
Guggenheim raises Alumis stock to buy with $18 price target By Investing.com - Investing.com Canada
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
Alumis resumed with a Buy at Guggenheim - TipRanks
Guggenheim raises Alumis stock to buy with $18 price target - Investing.com
Jane Street Group LLC Lowers Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Bank of America Corp DE - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Two Sigma Advisers LP - Defense World
Wellington Management Group LLP Invests $567,000 in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2024 in Acelyrin LawsuitSLRN - ACCESS Newswire
ProShare Advisors LLC Purchases 5,617 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Deutsche Bank AG - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Ameriprise Financial Inc. - Defense World
Alumis resumed with an Overweight at Morgan Stanley - TipRanks
BNP Paribas Financial Markets Invests $236,000 in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Northern Trust Corp Grows Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc.(NasdaqGS: SLRN) dropped from S&P TMI Index - marketscreener.com
Acelyrin, Inc.(NasdaqGS: SLRN) dropped from S&P Global BMI Index - marketscreener.com
Alumis completes merger with ACELYRIN, extends cash runway By Investing.com - Investing.com Canada
Alumis completes merger with ACELYRIN, extends cash runway - Investing.com Australia
Alumis Completes Merger With ACELYRIN, Strengthens Pipeline And Cash Runway - Nasdaq
Alumis, Acelyrin Close Merger - marketscreener.com
Alumis Inc. Completes Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Completes Merger and Delists from Nasdaq - TipRanks
Alumis Inc. Completes Merger with ACELYRIN, Inc. to Strengthen Pipeline in Immune-Mediated Disease Therapies - Nasdaq
Alumis completes merger with Acelyrin - TipRanks
Alumis Completes Merger with ACELYRIN - TradingView
Alumis-ACELYRIN Merger Creates Powerhouse in Immune Disease Drug Development with 2027 Cash Runway - Stock Titan
ACELYRIN Stockholders Approve Merger with Alumis - TipRanks
Alumis Inc. Stockholders Approve Merger with ACELYRIN - TipRanks
Dimensional Fund Advisors LP Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India
Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India
Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com
Alumis Stockholders Approve Merger with ACELYRIN - The Manila Times
Alumis wins shareholder nod for ACELYRIN merger - Investing.com
ACELYRIN shareholders approve Alumis merger deal - Investing.com
Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq
Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider
Alumis-ACELYRIN Merger Gets Green Light: Major Breakthrough for Immune Disease Treatment Pipeline - Stock Titan
Hsbc Holdings PLC Makes New $36,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (SLRN) Projected to Post Earnings on Tuesday - Defense World
Barclays PLC Increases Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Wells Fargo & Company MN Grows Holdings in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
INVESTOR ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Finanzdaten der Acelyrin Inc-Aktie (SLRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):